| T2610L |
BMS-599626 2HCL(714971-09-2 Free base)
|
1781932-33-9
|
98%
|
|
|
BMS-599626 2HCL (AC480 2HCl) is a BMS-599626 derivative. BMS-599626 is an orally available and selective dual inhibitor of HER1 and HER2 with IC50s of 20 and 30 ...
|
| T11966 |
MCHR1 antagonist 2
|
863115-70-2
|
98%
|
|
|
MCHR1 antagonist 2 is an antagonist of melanin-concentratin hormone receptor 1(MCH1-R, IC50 = 65 nM) and also inhibits hERG.
|
| T76796 |
Patritumab
|
1262787-83-6
|
98%
|
|
|
Patritumab (U3-1287) is an anti-HER3 monoclonal antibody with potential antitumor activity and inhibits phosphorylation of EGFR, HER2, HER3, ERK, and AKT.Patritu...
|
| T4612 |
NS309
|
18711-16-5
|
|
|
|
NS309 is a nonselective activator of small- and intermediate-conductance Ca2+-activated K+ (SK/KCa2 and IK/KCa3.1) channels (EC50s range from 0.12-1.2 µM for SK ...
|
| T12912 |
Sigma-1 receptor antagonist 3
|
1639220-17-9
|
100%
|
|
|
Sigma-1 receptor antagonist 3 is a potent and selective antagonist of Sigma-1 (σ1) receptor(Ki : 1.14 nM), has the potential for the neuropathic pain.
|
| T5390 |
BMS-599626 Hydrochloride
|
873837-23-1
|
100%
|
|
|
BMS-599626 Hydrochloride (AC480 Hydrochloride) is an orally bioavailable inhibitor of the HER1, HER2 and HER4 tyrosine kinases (IC50 =22, 32 and 190 nM, respecti...
|
| T8189 |
Dihydroberberine
|
483-15-8
|
93.77%
|
|
|
Dihydroberberine has anti-atherosclerotic, anti-inflammatory, hypolipidemic and antitumor activities. It inhibits human ether-a-go-go-related gene (hERG) channel...
|
| T30260 |
AZD-5672
|
780750-65-4
|
95.58%
|
|
|
AZD-5672 is an antagonist of CCR5 with an IC50 of 0.32 nM. AZD-5672 inhibits hERG cardiac ion channel binding and P-gp-mediated digoxin transport with IC50s of 7...
|
| T2325 |
Neratinib
|
698387-09-6
|
96.17%
|
|
|
Neratinib (HKI-272) (HKI-272) is an orally available, irreversible tyrosine kinase inhibitor for HER2 and EGFR (IC50: 59/92 nM), respectively.
|
| T13088 |
Tarloxotinib bromide
|
1636180-98-7
|
97.15%
|
|
|
Tarloxotinib bromide (TH-4000) is an irreversible inhibitor of EGFR/HER2.
|
| T35901 |
EGFR-IN-99
|
2068806-31-3
|
97.75%
|
|
|
EGFR-IN-99 (JBJ-03-142-02) is an EGFR and HER2 Exon 20 insertion mutation inhibitor with antiproliferative activity for the study of non-small cell lung cancer (...
|
| T7819 |
TAS0728
|
2088323-16-2
|
97.78%
|
|
|
TAS0728 is a HER2 inhibitor, with antitumor activity
|
| T2630 |
Poziotinib
|
1092364-38-9
|
97.81%
|
|
|
Poziotinib (NOV120101)(NOV120101; HM781-36B) is an irreversible HER1/2/4 inhibitor (IC50s: 3/5/23 nM).
|
| T3673 |
Mollugin
|
55481-88-4
|
98%
|
|
|
Mollugin (Rubimaillin) may be a JAK2 inhibitor and inhibits LPS-induced inflammatory responses by blocking the activation of the JAK-STAT pathway. Mollugin as a ...
|
| T69534 |
Zongertinib
|
2728667-27-2
|
98%
|
|
|
Zongertinib is a human HER2-selective tyrosine kinase inhibitor, a novel TK that is highly selective for covalent binding to the HER2 tyrosine kinase domain (TKD...
|
| T14380 |
AZD7507
|
1041852-85-0
|
98.01%
|
|
|
AZD7507 is a CSF-1R inhibitor with an IC50 of 32 nM. AZD7507 has antitumor activity.
|
| T12594 |
Pyrotinib dimaleate
|
1397922-61-0
|
98.07%
|
|
|
Pyrotinib dimaleate (SHR-1258 dimaleate) is a potent and selective dual inhibitor of EGFR/HER2 with IC50s of 13 and 38 nM, respectively.
|
| T63643 |
BI-4142
|
2682003-36-5
|
98.09%
|
|
|
BI-4142 is an orally active, potent and selective HER2 inhibitor that inhibits cancer cell proliferation, suppresses her2-dependent cell lines and inhibits downs...
|
| T2518 |
ARRY-380 (analog )
|
937265-83-3
|
98.22%
|
|
|
ARRY-380 analog (HER2-Inhibitor-1) is a potent and selective HER2 inhibitor.
|
| T4S0544 |
Furanodienone
|
24268-41-5
|
98.32%
|
|
|
1. Furanodienone has effects on MCF-7 cells are mediated, at least in part, by inhibiting ERα signaling. 2. Furanodienone inhibits EGFR/HER2 signaling pathway in...
|
